Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 3/20 | 0.31 |
| ▸ | DHODH | Q02127 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL3539453 | 0.84 | PARP1 (0.32) | PARP1RORCDHODHMAPTTSHR | |
| SCHEMBL3536160 | 0.83 | TSHR (0.34) | PARP1MAPTTSHRTP53 | |
| SCHEMBL3538767 | 0.82 | PSEN1 (0.33) | PARP1RORCDHODHMAPTTSHR | |
| SCHEMBL3542177 | 0.78 | NPC1 (0.30) | — | |
| SCHEMBL3539299 | 0.75 | ALDH1A1 (0.35) | MAPTTP53POLBLMNA | |
| SCHEMBL3536181 | 0.74 | PSEN1 (0.32) | TSHR | |
| SCHEMBL13314778 | 0.67 | PARP1 (0.45) | PARP1DHODHMAPTTSHRTP53 | |
| Formic Acid SCHEMBL3538430 | 0.67 | PARP1 (0.43) | PARP1DHODHMAPTTSHRTP53 | |
| SCHEMBL3539844 | 0.66 | PARP1 (0.44) | PARP1DHODHMAPTTSHRPOLB | |
| SCHEMBL13314787 | 0.66 | PARP1 (0.44) | PARP1DHODHMAPTTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | PARP1 2737/4885RORC 4183/4885DHODH 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.